Weill Cornell Leukemia Program

Home
United States
New York, NY
Weill Cornell Leukemia Program

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Weill Cornell Leukemia Program, Hospital, 520 East 70th Street, Starr Pavilion, 3rd Floor, New York, NY.

The Leukemia Program provides:

--A multidisciplinary team with specialists in infectious diseases, geriatrics, gastroenterology, cardiology, nephrology, neurology, pulmonary and critical care medicine, psychiatry, social work, nutrition and others

--Emphasis on highly personalized, individual care

--Close collaboration with comprehensive bone marrow and stem cell transplantation program

--Acce

ss to cutting edge clinical trials involving newly developed drugs, biological therapies and antibodies

--Specialized in-patient and out-patient units with highly trained staff and ancillary professionals experienced with the specific needs of these patients

--Extensive collaborations with world-renowned translational scientists, specific expertise in leukemia stem cells, genomics, epigenetics

--Specialized focus on development of clinical trials targeting leukemia stem cells, both at the time of diagnosis as well as trying to target and eradicate left-over leukemia stem cells in patients already in remission. The Leukemia Fighters Fund accepts charitable donations which are completely and specifically for leukemia research at Weill Cornell, has already provided funds for new recruits, novel treatment protocols, equipment and other critical needs

06/24/2026

FRIDAY, June 5, 2026 (HealthDay News) — An already available two-pill combo treats leukemia just as well as IV drugs, which should make cancer treatment easier

06/22/2026

ICYMI: An all-oral treatment regimen for older adults with acute myeloid ( ) received U.S. Food and Drug Administration approval based on led by Dr. Gail Roboz recently published in The New England Journal of Medicine. Get the breakdown via The ASCO Post

An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to fi...

06/15/2026

led by Dr. Gail Roboz published in The New England Journal of Medicine showed that an oral treatment combination was effective for older adults with acute myeloid ( ) leading to U.S. Food and Drug Administration approval: https://bit.ly/49XHQJ9 (cc: U.S. News and World Report)

US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.

06/05/2026

Congratulations to Dr. Pinkal Desai for being awarded the Weill Cornell Medicine Jeanne and Herbert Siegel Faculty Development Award for her exemplary clinical and research contributions! https://bit.ly/42EO3FT

06/04/2026

Dr. Gail Roboz at Weill Cornell Medicine led published in The New England Journal of Medicine showing that an all-oral drug combination for older patients with acute myeloid ( ) is an effective alternative to current standard of care, leading to recent U.S. Food and Drug Administration approval:

The ASCERTAIN V clinical trial, led by Weill Cornell Medicine researchers, demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatm...

06/02/2026

Dr. Bar-Natan gave insights into Weill Cornell Medicine characterizing patients with acute lymphoblastic (ALL) who don’t achieve a complete remission after their first cycle of treatment: https://bit.ly/3RIjaxW

04/21/2026

On , our Weill Cornell Medicine team is sharing our dedication to caring for those impacted by acute myeloid leukemia ( ). We are committed to supporting and advancing for patients, caregivers, and loved ones impacted by this type of Know AML

04/10/2026

In another episode of the Targeted Oncology , Dr. Gail Roboz talks about combination strategies for NPM1-mutant acute myeloid ( ):

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

04/07/2026

Dr. Gail Roboz joined the Targeted Oncology Treating Together to discuss the changing treatment landscape for relapsed/refractory NPM1-mutant acute myeloid ( ). Listen here:

Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia.

03/09/2026

Dr. Justin Kaner chimed in on preclinical data looking at a potential treatment for acute myeloid ( ): https://bit.ly/4skcx1O (cc: Medscape )

Structural nanomedicine — what helped give us the COVID vaccine — may now be the key to a potent blood cancer treatment that’s had remarkable early results.

Address

520 East 70th Street, Starr Pavilion, 3rd Floor
New York, NY
10021

Telephone

+16469622700

Website

https://weillcornell.org/leukemia

Alerts

Be the first to know and let us send you an email when Weill Cornell Leukemia Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Lauren Minchen Nutrition
280 Madison Avenue
Dr. Paul Gregory, DDS
57 W 57th Street